Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …

Epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth and
differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is …

Approximately 213,380 new cases of non-small-cell lung cancer (NSCLC) were estimated to
occur in the USA in 2007, which caused 160,390 NSCLC-related deaths. The majority of …

Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …

Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …

Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

Learning Objectives After completing this course, the reader will be able to: Describe the
molecular mechanism of action of erlotinib. Define clinical and molecular predictors of …

Erlotinib is an orally administered small-molecule inhibitor of EGF receptor (EGFR) tyrosine
kinase that is approved for the treatment of non-small-cell lung cancer (NSCLC) and …

Erlotinib (Tarceva™, OSI-774; Pfizer, Inc.) is an orally-active, targeted inhibitor of the
epidermal growth factor receptor (EGFR/HER1), which is part of a key regulatory pathway in …

BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …